Actively Recruiting
Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
Led by Yi Zhang · Updated on 2026-03-12
266
Participants Needed
4
Research Sites
131 weeks
Total Duration
On this page
Sponsors
Y
Yi Zhang
Lead Sponsor
T
The First People's Hospital of Yunnan
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine tests were performed once every 7 days for all patients within 100days. For patients with Hemorrhagic cystitis (HC), daily severity grading, pain scoring, cystitis symptom scoring, use of antispasmodic and analgesic medications, and major TCM evidence were recorded with the aim of evaluating the efficacy of moxibustion in the prevention of HC in this patient population.
CONDITIONS
Official Title
Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who understand the study, participate voluntarily, and sign informed consent
- Age between 14 and 60 years
- Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or with severe aplastic anemia undergoing allo-HSCT
You will not qualify if you...
- Patients who refuse to participate in the study
- Skin at the moxibustion sites is broken or sensitive
- Patients pretreated with the reduced-intensity conditioning (RIC) program before allo-HSCT
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Zhengzhou, Henan, China, 450002
Actively Recruiting
2
Yi Zhang
Wuhan, Hubei, China, 430000
Actively Recruiting
3
Hematology Department, The First People's Hospital of Yunnan
Kunming, Yunnan, China, 650032
Actively Recruiting
4
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Hangzhou, Zhejiang, China, 311121
Not Yet Recruiting
Research Team
Y
Yi Zhang, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here